Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

To investigate the role of an activated K-Ras gene in the initiation and maintenance of lung adenocarcinomas, we developed transgenic mice that express murine K-Ras4b(G12D) under the control of doxycycline in type II pneumocytes. Focal proliferative lesions of alveolar type II pneumocytes were observed as early as seven days after induction with doxycycline; after two months of induction, the lungs contained adenomas and adenocarcinomas, with focal invasion of the pleura at later stages. Removal of doxycycline caused a rapid fall in levels of mutant K-Ras RNA and concomitant apoptotic regression of both the early proliferative lesions and the tumors. Tumor burden was dramatically decreased by three days after withdrawal, and tumors were undetectable after one month. When similar experiments were performed with animals deficient in either the p53 gene or the Ink4A/Arf locus, tumors arose more quickly (within one month of exposure to doxycycline) and displayed more obvious histological features of malignancy; nevertheless, these tumors also regressed rapidly when the inducer was removed, implying that continued production of mutant K-Ras is necessary to maintain the viability of tumor cells in the absence as well as the presence of tumor suppressor genes. We also show that the appearance and regression of these pulmonary tumors can be readily monitored in anesthetized transgenic animals by magnetic resonance imaging.

[1]  Ming You,et al.  Wildtype Kras2 can inhibit lung carcinogenesis in mice , 2001, Nature Genetics.

[2]  A. Fornace,et al.  Genomic instability and the role of p53 mutations in cancer cells. , 1995, Current opinion in oncology.

[3]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[4]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[5]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[6]  D A Benaron,et al.  Imaging transgenic animals. , 1999, Annual review of biomedical engineering.

[7]  R. Gillies,et al.  Applications of magnetic resonance in model systems: cancer therapeutics. , 2000, Neoplasia.

[8]  J. Minna,et al.  Molecular detection of early lung cancer. , 1999, Journal of the National Cancer Institute.

[9]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[10]  A. Malkinson,et al.  Genetic studies on lung tumor susceptibility and histogenesis in mice. , 1991, Environmental health perspectives.

[11]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[12]  T. Jacks,et al.  Modeling human lung cancer in mice: similarities and shortcomings , 1999, Oncogene.

[13]  J. Melo,et al.  Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[14]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[15]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[16]  E. Campo,et al.  Ki‐ras gene mutations and absence of p53 gene mutations in spontaneous and urethane‐induced early lung lesions in CBA/J mice , 1998, Molecular carcinogenesis.

[17]  S. Lowe,et al.  INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .

[18]  C. Halbert,et al.  Keratinocyte growth factor stimulates transduction of the respiratory epithelium by retroviral vectors. , 1999, Human gene therapy.

[19]  K. Vousden,et al.  Minireviewp 53 : Death Star able to induce the defensive p 53 response to oncogene , 2000 .

[20]  J. Tichelaar,et al.  Conditional Expression of Fibroblast Growth Factor-7 in the Developing and Mature Lung* , 2000, The Journal of Biological Chemistry.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[23]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[24]  J. Ward,et al.  Origin of spontaneous and transplacentally induced mouse lung tumors from alveolar type II cells. , 1991, Experimental lung research.

[25]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[26]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[27]  B. Stripp,et al.  Phenotypic consequences of lung-specific inducible expression of FGF-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Pechacek,et al.  Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? , 1991, Journal of the National Cancer Institute.

[29]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[30]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[31]  Y. Yarden,et al.  Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 , 2001, Oncogene.

[32]  J. Minna,et al.  Molecular pathogenesis of lung cancer. , 1994, Annual review of physiology.

[33]  M. Tsao,et al.  Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  S. Lowe,et al.  Activation of p53 by oncogenes. , 1999, Endocrine-related cancer.

[35]  J. Whitsett,et al.  Aberrant processing of surfactant protein C in hereditary SP-B deficiency. , 1995, The American journal of physiology.

[36]  J Downward,et al.  Ras signalling and apoptosis. , 1998, Current opinion in genetics & development.

[37]  H. Varmus,et al.  Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[39]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[40]  W. W. Nichols,et al.  Activation of the Ki‐ras gene in spontaneous and chemically induced lung tumors in CD‐1 mice , 1992, Molecular carcinogenesis.

[41]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[42]  J. Tichelaar,et al.  FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[43]  T. Mohr,et al.  Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.

[44]  J. Whitsett,et al.  Transgenic models for study of pulmonary development and disease. , 1994, The American journal of physiology.